Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02334462 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali
A Phase 1 study of Malaria, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 538
- Enrollment target
- 2
- Study locations
NCT02334462 is a Phase 1 study of Malaria that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 538 participants, above the 238-participant average among 27 other Malaria trials with a reported enrollment target (126% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT02334462, a Phase 1 study of Malaria, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 538 participants
- Enrollment target
- 2
- Study locations
Study Summary
Background: \- Malaria is a severe infection caused by a parasite. People can get malaria if a mosquito that carries the parasite bites them. Malaria infection does not happen in the United States, but many people in Africa, Asia, and South America are at risk for it. Researchers want to test two vaccines that may help decrease malaria infection. Objective: \- To see if two vaccines (Pfs25M-EPA/Alhydrogel and Pfs230DIM-EPA/Alhydrogel ) are safe in humans and cause an immune response that will prevent malaria parasites from correctly growing in the mosquito. Eligibility: \- Healthy adults ages 18 50. Design: * There are several groups in this study. Each group will receive a different dose of the vaccine and some groups will received both vaccines. * Vaccinations will be given on two days about 4 weeks apart. * Participants will receive each vaccine as an injection into the arm. Blood will be drawn on the day of vaccination. * In the 4 weeks after receiving a vaccination, participants will have at least 3 clinic visits and 1 phone contact. They will have at least 3 more visits and 3 phone contacts over the next 6 months. * At each visit, participants will be evaluated for side effects to the vaccine and any new health changes or problems. They will be asked how they are feeling and if they have taken any medicine. Blood and urine samples may be taken at the visit. More follow-up visits may be needed to follow up on changes or problems.
Conditions Studied
Interventions
- BIOLOGICAL Pfs230D1M-EPA/Alhydrogel
- BIOLOGICAL Pfs25M-EPA/Alhydrogel
- DRUG TWINRIX
- DRUG Menactra
Study Locations (2)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Other
- Malaria Research and Training Center - Bamako
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 538 participants |
| Start Date | 2015-01-07 |
| Est. Completion | 2018-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02334462
The ClinicalTrials.gov registry entry for NCT02334462 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 538 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 238-participant average among 27 other Malaria trials with a reported enrollment target (126% higher). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malaria appearing as the primary indexed condition, and to 4 interventions - of which Pfs230D1M-EPA/Alhydrogel is the first listed.
NCT02334462 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Other.
Frequently Asked Questions
What is clinical trial NCT02334462 about?
NCT02334462 is a clinical study titled "Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali". Background: \- Malaria is a severe infection caused by a parasite. People can get malaria if a mosquito that carries the parasite bites them. Malaria infection does not happen in the United States, but many people in Africa, Asia, and South America are at risk for it. Researchers want to test two v...
What is the current status of trial NCT02334462?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 538 participants. The study started on 2015-01-07. Estimated completion is 2018-10-22.
What conditions does trial NCT02334462 study?
This clinical trial studies the following conditions: Malaria.
What interventions are being tested in trial NCT02334462?
The interventions under investigation include: Pfs230D1M-EPA/Alhydrogel (BIOLOGICAL), Pfs25M-EPA/Alhydrogel (BIOLOGICAL), TWINRIX (DRUG), Menactra (DRUG).
Who is sponsoring clinical trial NCT02334462?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02334462 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malaria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral E1018 in Healthy Adult Participants
RECRUITING · Phase 1
-
Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
RECRUITING · Phase 1
-
First-in-Human PfSPZ-LARC2 Vaccination/CHMI
ACTIVE NOT RECRUITING · Phase 1
-
A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria
ACTIVE NOT RECRUITING · Phase 1
-
Trial to Evaluate CIS43LS in Healthy Adults
COMPLETED · Phase 1
-
Blood-Stage Plasmodium Vivax Cell Bank
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.